- 专利标题： INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT
-
申请号： US17925493申请日： 2020-06-01
-
公开(公告)号： US20230183197A1公开(公告)日： 2023-06-15
- 发明人: Julian Blagg , Jon Roffey , Martin Drysdale , Paul Winship , David Clark
- 申请人： NeoPhore Limited
- 申请人地址： GB Cheshire
- 专利权人： NeoPhore Limited
- 当前专利权人： NeoPhore Limited
- 当前专利权人地址： GB Cheshire
- 优先权： GB 08201.2 2020.06.01
- 国际申请： PCT/GB2021/051349 2020.06.01
- 进入国家日期： 2022-11-15
- 主分类号： C07D295/16
- IPC分类号： C07D295/16 ; C07D239/26 ; C07D209/44 ; C07D207/12 ; C07D211/42 ; C07D213/16 ; C07D471/04 ; C07D231/12 ; C07D249/04 ; C07D401/12 ; C07D217/04 ; C07D217/16 ; C07D265/36 ; C07D209/08 ; C07D215/08 ; C07D405/12 ; C07D401/04 ; C07D403/12 ; C07D403/04 ; A61K45/06
摘要：
The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process:
wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 and/or PMS2 activity is implicated.
wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 and/or PMS2 activity is implicated.
信息查询
